Difference between revisions of "Betrixaban (Bevyxxa)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Direct factor Xa inhibitor. | + | Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208383s007lbl.pdf Betrixaban (Bevyxxa) package insert]</ref><ref>[[:File:Betrixaban.pdf | Betrixaban (Bevyxxa) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Venous_thromboembolism|VTE prevention]] |
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208383s007lbl.pdf Betrixaban (Bevyxxa) package insert]<ref name="insert"></ref> | |
| + | *[http://www.uptodate.com/contents/betrixaban-patient-drug-information Betrixaban (Bevyxxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/betrixaban-patient-drug-information Betrixaban (Bevyxxa) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2017-06-23: FDA approved for the prophylaxis of [[Venous thromboembolism|venous thromboembolism (VTE)]] in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. |
==Also known as== | ==Also known as== | ||
| Line 19: | Line 20: | ||
*'''Brand name:''' Bevyxxa | *'''Brand name:''' Bevyxxa | ||
| − | [[Category: | + | ==References== |
| + | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Direct oral anticoagulants]] | [[Category:Direct oral anticoagulants]] | ||
| Line 25: | Line 29: | ||
[[Category:Factor Xa inhibitors]] | [[Category:Factor Xa inhibitors]] | ||
| − | [[Category:Venous thromboembolism | + | [[Category:Venous thromboembolism medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2017]] |
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2017-06-23: FDA approved for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Also known as
- Code name: PRT-054021
- Brand name: Bevyxxa